Cardan Capital Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Cardan Capital Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-14,125	Closed	-$1.01M	–	189
2018 Q4	$1.01M	Buy	14,125 +1,430	+11%	+$115K	0.18%	92
2018 Q3	$1.22M	Buy	12,695 +600	+5%	+$58.2K	0.19%	86
2018 Q2	$1.15M	Buy	12,095 +1,036	+9%	+$95.2K	0.19%	84
2018 Q1	$970K	Buy	+11,059	New	+$1.01M	0.16%	87
2017 Q4	–	Sell	-7,680	Closed	-$665K	–	127
2017 Q3	$665K	Buy	7,680 +200	+3%	+$16K	0.13%	76
2017 Q2	$577K	Buy	7,480 +106	+1%	+$7.52K	0.11%	77
2017 Q1	$511K	Buy	7,374 +995	+16%	+$66.8K	0.11%	79
2016 Q4	$378K	Buy	6,379 +1,997	+46%	+$123K	0.08%	82
2016 Q3	$290K	Buy	+4,382	New	+$271K	0.06%	90

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Cardan Capital Partners's XBI Position: Q1 2019 in Review

Cardan Capital Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2019, closing a stake of 14,125 shares — an estimated $1.01M sold.

Cardan Capital Partners first reported a position in XBI in Q3 2016 and held it in 9 quarters. The position peaked at $1.22M in Q3 2018. 451 funds tracked by Wall St. Rank hold XBI as of Q1 2019.

Cardan Capital Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2019 after selling out during the quarter.
Cardan Capital Partners sold 14,125 State Street SPDR S&P Biotech ETF shares in Q1 2019, an estimated $1.01M.
Cardan Capital Partners first reported a position in State Street SPDR S&P Biotech ETF in Q3 2016 and held it in 9 quarters.
Cardan Capital Partners's State Street SPDR S&P Biotech ETF position peaked at $1.22M in Q3 2018.
451 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2019.

Based on Cardan Capital Partners's 13F filing for Q1 2019, filed 9 Apr 2019.